FindTrial
Sign In

Rogaratinib (BAY1163877)

DRUG6 trials

Sponsors

Bayer

Conditions

Advanced or Metastatic Solid TumorCancerCarcinoma, Transitional CellClinical Trial, Phase INeoplasmsPharmacokineticsUrothelial Carcinoma

Phase 1

Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
CompletedNCT03473756
BayerUrothelial Carcinoma
Start: 2018-05-15End: 2024-07-10Updated: 2025-04-09
Rogaratinib (BAY1163877) Human Mass Balance Study
CompletedNCT03484585
BayerClinical Trial, Phase I, Pharmacokinetics
Start: 2018-04-06End: 2018-08-09Updated: 2018-08-14
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
CompletedNCT03517956
BayerAdvanced or Metastatic Solid Tumor
Start: 2018-07-25End: 2021-02-01Updated: 2022-07-14
Rogaratinib (BAY1163877) in Chinese Patients
CompletedNCT03788603
BayerNeoplasms
Start: 2019-01-07End: 2020-04-14Updated: 2021-03-29

Phase 2

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma
CompletedNCT03410693
BayerCarcinoma, Transitional Cell
Start: 2018-05-31End: 2020-10-27Updated: 2022-09-28
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
CompletedNCT04125693
BayerCancer
Start: 2019-10-30End: 2021-02-16Updated: 2022-04-01

Related Papers

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With <i>FGFR</i> RNA-Overexpressing Urothelial Cancer
JAMA Oncology2024-09-199 citations
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression
Journal of Clinical Oncology2022-10-1489 citations
Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and <i>FGFR</i> mRNA overexpression in the phase Ib/II FORT-2 study.
Journal of Clinical Oncology2021-05-2018 citations
Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and <i>FGFR</i> mRNA overexpression.
Journal of Clinical Oncology2020-05-2033 citations
FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on <i>FGFR1/3</i> mRNA expression.
Journal of Clinical Oncology2020-02-1934 citations
Abstract 3080: Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models
Experimental and Molecular Therapeutics2019-07-012 citations
Abstract 3080: Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models
Cancer Research2019-07-012 citations
Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
International Journal of Cancer2019-02-2688 citations
Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression
Annals of Oncology2018-10-017 citations
Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
Annals of Oncology2018-10-011 citations